At the same time, the final phase continues for a trial of Vertex’s zimislecel (formerly VX-880), a cell-based therapy that does require immunosuppression to protect the immune system from rejecting ...

Let's dive into some prime choices out of from the screener. Overview: Synopsys, Inc. is a company specializing in electronic design automation software for integrated circuits, with a market ...

Let's dive into some prime choices out of from the screener. Overview: Synopsys, Inc. is a company specializing in electronic design automation software for integrated circuits, with a market ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...